Efficacy and safety results from GEICO 1205, a randomized phase II trial of neoadjuvant chemotherapy with or without bevacizumab for advanced epithelial ovarian cancer

Autor:	Garcia, YG, de Juan Ferré A, Mendiola, C, Barretina-Ginesta, MP, Gaba Garcia L, Santaballa Bertrán A, Bover Barcelo I, Gil-Martin, M, Manzano, A, Rubio Pérez MJ, Romeo Marin M, Arqueros Núñez C, Garcia-Martinez, E, Gonzalez Martin A
Rok vydání:	2019
Předmět:	genetic structures bevacizumab complete macroscopic response rate interval debulking surgery neoadjuvant chemotherapy ovarian cancer sense organs eye diseases
Zdroj:	INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe instname
ISSN:	1048-891X
Popis:	Bevacizumab is an approved treatment after primary debulking surgery for ovarian cancer. However, there is limited information on bevacizumab added to neoadjuvant chemotherapy before interval debulking surgery.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::45b7a60a9d2602941c737cbe80acd930 https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=10360 Zobrazit plný text záznamu